Delivers additional access to fully covered preventative care for patients at increased risk for periodontal disease identified through PerioPredict.
Interleukin Genetics, Inc. a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced that it has signed an agreement with Reimbursement Specialists, Inc., a Comprehensive Benefit Administrators (CBA) company and leading provider of benefits management services, to include coverage for Interleukin’s PerioPredict® Genetic Risk Test as part of CBA’s Freedom Dental Plan.
PerioPredict identifies individuals at increased risk for severe periodontitis due to a genetic tendency to overproduce chronic inflammation, an underlying root cause of many chronic diseases. The test delivers genetic information that can improve risk stratification and support increased preventative dental care which, in turn, can significantly lower a patient’s systemic inflammatory burden and potentially reduce the risk of periodontitis and other chronic diseases.
PerioPredict testing through CBA’s Freedom Dental Plan will guide additional preventative care for patients with increased risk for developing severe periodontal disease as identified by a positive test result.
“We are thrilled to add an innovative new benefit that uses genetic testing to drive personalised care as a component to our Freedom Dental Plan,” said Mike McKenna, President and Chief Executive Officer of CBA. “This unique test will differentiate our plan, providing added value for current and prospective customers.”
“CBA is a perfect partner to extend PerioPredict in the New England market. Their team recognised early on the importance of integrating medical and dental sciences in a more holistic approach to health to improve wellness and ultimately reduce long-term health care costs,” said Mark Carbeau, Chief Executive Officer of Interleukin Genetics. “Adding PerioPredict as a covered benefit in CBA’s Freedom Dental Plan is yet another strong step forward for Interleukin as we continue to gain traction in the marketplace for our innovative testing and patient engagement programme. We are delighted to work with CBA to expand access to our PerioPredict test.”
Periodontal disease is one of the most common chronic inflammatory diseases in developed countries, and studies document that better control of the condition has been shown to significantly lower the systemic inflammatory burden. Studies also demonstrate that proper management of periodontitis substantially lowers medical costs for patients with certain chronic diseases.
